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Methods and Results. The present study used the data base of the Thrombolysis in Myocardial Infarction (TIMI) Phase I trial to correlate the presence or absence of angiographically documented collaterals in the initial hours of myocardial infarct evolution with the size of the infarct as assessed by serial measurements of serum creatine kinase (CK). To avoid the confounding effects of reperfusion on enzymatic estimates of infarct size, this report is limited to those 125 patients who failed to recanalize at 90 minutes after administration of tissue plasminogen activator or streptokinase. Patients with angiographically documented collaterals (group A, n=51) had significantly lower values of peak serum CK than patients without collaterals (group B, n=74) (1,877±216 versus 2,661±212 1U/l, respectively [mean±SEM], p=0.004). Similarly, CK-derived infarct size estimates were significantly lower in group A than in group B (20.6+2.5 versus 31.4±2.8 CK gram equivalents, p=0.001). The infarct size observed in patients with collaterals was less for anterior infarctions as well as for infarctions of other locations; thus, the beneficial effects of collaterals were independent of the site of the infarct. In 65 of the 125 patients who failed to reperfuse, left ventricular ejection fraction (LVEF) was assessed by contrast ventriculography both at initial cardiac catheterization (before thrombolytic therapy) and at hospital discharge. Among the patients who had both studies, global LVEF tended to increase from pretreatment to hospital discharge in group A (from 50.6±1.8% to 53.4+ 1.8%,p=0.10) but decreased in group B patients (from 50.3±1.8% to 47.8± 1.7%, p =0.02). At hospital discharge, global LVEF was greater in patients with coronary collaterals (53.5+1.7% versus 49.6+1.7%,p=0.01).
Conclusions. The results demonstrate that, in patients in whom thrombolytic therapy fails to induce reperfusion, the presence of coronary collateral vessels at the onset of myocardial infarction is associated with limitation of infarct size as assessed enzymatically and with improved ventricular function on discharge as assessed by LVEF. (Circulation 1991; 83:739-746) It is well established that coronary collateral blood flow is a major determinant of the extent of necrosis after coronary artery occlusion in experimental animals.1-3 However, the role of coronary collaterals in modulating infarct size in humans ation of kinetics of creatine kinase (CK) release by reperfusion,13-6 and reliance on global left ventricular function parameters despite the poor correlation between recovery of regional wall motion in the infarct site and improvement in global left ventricular ejection fraction after thrombolytic therapy. 17 No previous study has examined the impact of collateral vessels present at the onset of acute myocardial infarction on infarct size, estimated enzymatically, in the absence of any confounding effect due to reperfusion.
The Thrombolysis in Myocardial Infarction (TIMI) Phase I trial provided a unique opportunity to investigate the functional significance of coronary collaterals present during the first few hours of myocardial infarction. In this trial, patients with evolving myocardial infarction underwent coronary angiography immediately after enrollment and had See p 1084 serial measurements of serum CK throughout the subsequent 72 hours. Acute coronary angiography made it possible to determine 1) whether the infarctrelated artery was completely occluded in the early phase of myocardial infarction, 2) whether angiographically detectable collateral vessels were present at this time, and 3) whether the thrombolytic agent was effective in inducing thrombolysis. Given that intravenous thrombolytic therapy is now recommended in acute myocardial infarction, it is unlikely that it would be feasible to repeat this study presently or in the future. Accordingly, the objective of the present study was to correlate the presence or absence of coronary collaterals in the acute phase of myocardial infarction with the size of the infarct as assessed by serial measurements of serum CK. To avoid the interference of reperfusion on CK kinetics,13-16 the analysis was limited to those 125 patients who failed to recanalize at 90 minutes after the administration of recombinant tissue-type plasminogen activator (t-PA) or streptokinase.
Methods
The TIMI Phase I trial was a multicenter randomized prospective trial, sponsored by the National Heart, Lung, and Blood Institute and designed to compare the efficacy of intravenous t-PA and streptokinase in achieving reperfusion in patients with acute myocardial infarction. Phase I began on August 15, 1984 , and was stopped prematurely on February 5, 1985 , because the reperfusion rate after treatment with t-PA was significantly greater than that with streptokinase. The 
Data Analysis
The perfusion status of the infarct-related artery was assessed by the radiographic core laboratory using standardized TIMI criteria.1819 Successful reperfusion was defined as TIMI perfusion grade 2 or 3 at 90 minutes after initiation of thrombolytic therapy. Collaterals to the infarct-related artery were evaluated from the acute pretreatment coronary angiogram. Collaterals were analyzed by the radiographic core laboratory and graded on a threepoint scale as absent (grade 1), minimal (grade 2), or well developed (grade 3), respectively. Grade 1 was defined as the absence of any collaterals to the occluded vessel supplying the area of infarction. Grade 2 collaterals were defined as collaterals resulting in faint opacification to a diameter not exceeding 1 mm in the occluded vessel or its branches, visualized distal to the obstruction in the occluded vessel supplying the area of the infarct. Well-developed collaterals (grade 3) were defined as collaterals resulting in full opacification to a diameter greater than 1 mm in the occluded vessel or its branches, visualized distal to the obstruction in the occluded vessel that supplies the area of the infarction. A patient was considered to have collaterals to the infarct-related artery if the collateral perfusion grade was 2 or 3. Collaterals were graded in this manner only in the acute pretreatment film. Two hundred ninety patients were enrolled in TIMI Phase I. Of these 290 patients, 57 (20%) had pretreatment TIMI perfusion grade 2 or 3 in the infarct-related artery. One patient did not have the 90-minute reading. Among the remaining 232 patients with pretreatment perfusion grade 0 or 1 in the infarct-related artery, successful reperfusion at 90 minutes after thrombolytic therapy occurred in 107 patients (70 of 113 patients treated with t-PA and 37 of 119 patients treated with streptokinase). Thus, 125 patients had TIMI perfusion grade 0 or 1 both before and 90 minutes after initiation of thrombolytic therapy. These patients who had initial coronary occlusion and failed to exhibit reperfusion form the basis of the present report.
CK Enzyme Determination and Estimation of Infarct Size
All patients enrolled had serial serum CK enzyme levels measured at 4-hour intervals for the first 48 hours after randomization at each of the participating clinical sites. Total serum CK activity was assessed by the Rosalki method.20 Infarct size was estimated from changes in serum CK, as previously described.21 Peak serum CK and estimates of infarct size were compared in patients with collaterals (group A) and in those without collaterals (group B). Infarct size could not be estimated in 11 of 125 patients because of incomplete serum CK data.
Statistical Methods
All values are expressed as mean+SEM. (Figure 1 ). These differences in serum CK activity and infarct size were highly significant (p=0.004 and 0.001, respectively). Infarct size in group A was approximately 35% less than infarct size in group B.
The beneficial effect of collaterals on infarct size was independent of infarct location (Figure 2 effort was made to take into account these missing data. Since these patients presumably had large infarctions, they were assigned the largest peak CK and infarct size values observed in the present study. When the analysis of peak CK and infarct size was repeated after including these three patients, the results were similar to those described above; that is, peak serum CK and CK-derived infarct size were significantly lower in group A than in group B.
Since only four patients in group A had welldeveloped (grade 3) collaterals, a statistical analysis In TIMI Phase I, successful reperfusion occurred in 62% of the patients treated with t-PA and in 31% of those treated with streptokinase. Thus, over a third of the patients treated with t-PA and two thirds of the patients treated with streptokinase did not experience early recanalization. The present results suggest that, in these patients, adjunctive mechanical or pharmacological interventions aimed at improving collateral blood flow in the early hours of infarct evolution could be beneficial by limiting the final extent of myocardial necrosis.
Use of Serum CK to Estimate Infarct Size
Myocardial infarct size, estimated enzymatically using serial serum CK determinations, is an objective end point for assessing interventions in patients with acute myocardial infarction and correlates with acute and long-term morbidity and mortality.25-29 However, reperfusion is associated with altered kinetics of CK release, both experimentally and clinically.13-161n experimental animals, early reperfusion is associated with higher serum CK levels that peak earlier than those associated with sustained occlusion, reflecting a more rapid release of CK from myocardial tissue.13 A similar pattern is observed in patients. For example, in the 272 patients enrolled in TIMI Phase I, reperfusion was associated with peaking of serum CK levels within 4 hours after thrombolytic therapy: 82% of patients with peaking of CK levels within 4 hours had angiographic evidence of reperfusion compared with 19% of those with peaking of CK levels 16 hours or more after thrombolytic therapy.36 In view of these alterations of CK kinetics, the validity of CK-derived measurements of infarct size in the setting of reperfusion remains to be established. Consequently, in the present study, we have limited the analysis to those patients who had no angiographic evidence of reperfusion (as defined by TIMI perfusion grade 0 or 1) at 90 minutes after initiation of thrombolytic therapy. Peak serum CK enzyme levels and CKderived infarct size in these patients are likely to accurately reflect the extent of myocardial necrosis.
Reperfusion occurring after 90 minutes of thrombolytic therapy but before 48-72 hours from the onset of symptoms could still affect enzymatic estimates of infarct size. However, time to peak CK and incidence of late recanalization (as assessed by predischarge coronary angiography) did not differ in patients with and without coronary collaterals, indicating that the occurrence of reperfusion between 90 minutes and hospital discharge was similar in both groups. The similarity of time to peak CK between groups A and B also indicates that the presence of collateral circulation did not result in faster "washout" of CK from infarcted myocardium.
Previous Studies
Two prior studies1737 have examined the relation between presence of coronary collaterals and regional and global left ventricular function in the TIMI Phase I trial. In the report by Sheehan et al,17 left ventricular global and regional wall motion were evaluated by contrast ventriculography before treatment and at hospital discharge in 145 patients. Overall, global left ventricular ejection fraction increased (from 48.7±+ 1.7% to 50.9-+ 1.6%, p=0.06) in 43 patients with collaterals (collateral perfusion grade 2 or 3) but remained unchanged in 102 patients without collaterals (from 48.6+1.0% to 48.9+1.1%). These findings are in agreement with our present results obtained in the subset of TIMI I patients who failed to reperfuse at 90 minutes.
In that previous report,17 the higher global left ventricular ejection fraction at hospital discharge in TIMI patients with coronary collaterals was not attributed to differences in the degree of recovery of wall motion in the infarct site. One possible interpretation of this finding is that coronary collaterals did not limit infarct size. In the present study, however, enzymatic estimates of infarct size in the cohort of TIMI patients in whom thrombolytic therapy did not effect reperfusion showed a significantly smaller infarct size in patients with coronary collaterals. The apparent discrepancy between this prior report17 and the present study may be related to the different populations examined (all treated patients, regardless of the occurrence of reperfusion, in the report by Sheehan et al,17 versus patients who failed to reperfuse in the present study). It is possible that the beneficial effect of collaterals can be more readily demonstrated in the presence of sustained coronary occlusion. In patients in whom the extent of necrosis is limited by reperfusion, the impact of collaterals may be less important. Furthermore, the analysis of regional wall motion in the infarct territory used by Sheehan et al17 is an indirect means of assessing infarct size.
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In the second report, 37 Wackers et al used quantitative radionuclide angiography to assess left ventricular function in 229 TIMI I patients. No difference in global left ventricular ejection fraction was found between patients with and without collaterals. Regional left ventricular ejection fraction in the infarct territory was also similar in both groups. This study, however, did not selectively analyze global or regional left ventricular function in the cohort of TIMI patients who failed to reperfuse after thrombolytic therapy. In contrast, the present study was designed to evaluate the role of coronary collaterals in that specific cohort of TIMI patients. As mentioned above, it is conceivable that collaterals limit infarct size in patients in whom thrombolytic therapy fails to produce reperfusion but not in patients who experience early recanalization.
Other investigators38,39 have evaluated the role of coronary collaterals in the recovery of global and regional left ventricular function after various acute reperfusion interventions such as intravenous or intracoronary streptokinase, percutaneous transluminal coronary angioplasty, or emergency coronary artery bypass surgery. Despite the small number of patients reported and the variable modalities of reperfusion used, patients with well-developed coronary collaterals had a significant improvement in global left ventricular ejection fraction, whereas those without collaterals had no improvement. A recent preliminary report40 suggests that the presence of coronary collaterals may reduce the development of postinfarction aneurysm.
A protective effect of coronary collaterals in acute myocardial infarction in humans was also suggested in a postmortem study of hours of symptom onset, thereby eliminating the potential disparity in collateral visualization due to variable timing of coronary arteriography after myocardial infarction.
In experimental animals, it is well established that coronary collateral blood flow is a major determinant of the extent of necrosis after acute coronary artery occlusion.1-3 However, the influence of collaterals on infarct size, left ventricular global and regional systolic function, and clinical outcome after acute myocardial infarction in humans remains unsettled. A beneficial effect of coronary collaterals on infarct size has been suggested by many clinical investigators4-6,10,38,39 but not by others.7-9,11,12 This apparent controversy may be related to one of the following factors: different techniques used to visualize coronary collaterals, variable timing of coronary arteriography after acute myocardial infarction, limitations of enzymatic estimates of infarct size in patients with spontaneous or induced reperfusion, use of indirect means of assessing infarct size (such as regional wall motion or ejection fraction), and inclusion of patients with previous manifestations of myocardial ischemia such as angina or healed myocardial infarction. The TIMI Phase I study addresses many of these limitations. All patients included in this report had a persistently and totally occluded infarct-related artery despite thrombolytic therapy, thus making angiographic visualization of coronary collaterals more feasible. Moreover, enzymatic estimates of myocardial infarct size using serial serum CK levels are more reliable in the absence of reperfusion.13-16 All patients in this report were enrolled within 7 hours after the onset of symptoms of acute myocardial infarction and underwent coronary arteriography immediately thereafter. The present results, together with previous studies that focused specifically on the early phase of acute myocardial infarction,38,39 provide strong evidence that coronary collaterals do indeed limit ischemic injury.
Implications
The present analysis of data from this large multicenter double-blind trial is the first study to demonstrate a protective effect of coronary collateral vessels on enzymatically estimated infarct size. These findings should stimulate further research to investigate the role of various pharmacological interventions aimed at salvaging myocardial tissue by increasing coronary collateral blood flow or by enhancing collateral growth.
